MedTrace Logo

Study of T3 on the Incidence of Atrial Fibrillation in Patients Undergoing Cardiac Surgery

NCT00289367 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2008-05-20

No results posted yet for this study

Summary

The purpose of this project is to see whether treatment with a thyroid hormone, called triiodothyronine or T3, following open heart surgery reduces the risk of developing atrial fibrillation.

Conditions

Interventions

DRUG

Triiodothyronine

0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.

DRUG

triiodothyronine

IV formulation - Triostat, 0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.

Sponsors & Collaborators

  • Thomas and Jeanne Elmezzi Foundation

    collaborator OTHER

  • Northwell Health

    lead OTHER

Principal Investigators

  • Irwin Klein, MD · North Shore University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2006-08-31
Completion
2008-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00289367 on ClinicalTrials.gov